Targets for immunotherapy of liver cancer

Slides:

Advertisements

Similar presentations

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep

Advertisements

Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Socializing Individualized T-Cell Cancer Immunotherapy

Radioembolization for hepatocellular carcinoma

Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders Mai F. Tolba, Hany A.

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Immunotherapy of hepatocellular carcinoma

Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials Pippa Newell, Augusto Villanueva, Josep M. Llovet

Volume 71, Issue 2, Pages (February 2017)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Radiation-induced effects on tumour cells

The yin and yang of evasion and immune activation in HCC

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.

Figure 3 Altered adaptive immune functions after sepsis

Figure 1 Four nodes to target when inducing anti-tumour immunity

Figure 7 Clinical options for HCC therapy

Oncology Meets Immunology: The Cancer-Immunity Cycle

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Classification of immunotherapies

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Markers of cancer cell and lymphocytes in inflammatory infiltration around a tumour as potential markers of immunomodulatory treatment response. Markers.

Figure 6 Combination therapy for HCC

Volume 56, Issue 3, Pages (March 2012)

Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD

Regulatory T-cell directed therapies in liver diseases

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Nat. Rev. Urol. doi: /nrurol

Living donor liver transplantation: is the hype over?

Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.

Volume 68, Issue 1, Pages (January 2018)

Regulatory T-cell directed therapies in liver diseases

Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC

Hepatitis C core protein – The “core” of immune deception?

Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges Marie-Louise Michel, Qiang Deng,

Nat. Rev. Rheumatol. doi: /nrrheum

Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer

Volume 68, Issue 3, Pages (March 2018)

Figure 2 Site of action of checkpoint inhibitors and agonists being

Takehito Shukuya, MD, PhD, David P. Carbone, MD, PhD

Primary biliary cirrhosis: A 2010 update

The yin and yang of evasion and immune activation in HCC

Robert J Korst, MD, Ronald G Crystal, MD

Volume 45, Issue 4, Pages (October 2006)

Radioembolization for hepatocellular carcinoma

Nat. Rev. Endocrinol. doi: /nrendo

Dendritic cells: regulators of hepatic immunity or tolerance?

Targeting STAT3 in hepatocellular carcinoma: Sorafenib again…

Molecular prognostication of liver cancer: End of the beginning

Figure 1 Mechanisms of action of immunotherapy modalities

Duality of the Immune Response in Cancer: Lessons Learned from Skin

Nat. Rev. Urol. doi: /nrurol

Combined locoregional-immunotherapy for liver cancer

Figure 3 Underlying mechanisms of TREG cells in atherosclerosis

New trials and results in systemic treatment of HCC

Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide

Mechanism of PD-1/PD-L1 pathway-induced immunosuppression within the tumour microenvironment. Mechanism of PD-1/PD-L1 pathway-induced immunosuppression.

Genetics of hepatocellular carcinoma: The next generation

Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;

Releasing the Brakes on Cancer Immunotherapy

Stefan Schülke, PhD, Stefan Vieths, PhD

Figure 4 Molecular signalling and immunological

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.

Advances and highlights in mechanisms of allergic disease in 2015

بسم الله الرحمن الرحيم.

Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma Guillermo de Velasco, Axel Bex, Laurence Albiges, Thomas Powles, Brian.

Presentation transcript:

Targets for immunotherapy of liver cancer Tim F. Greten, Bruno Sangro Journal of Hepatology Volume 68, Issue 1, Pages 157-166 (January 2018) DOI: 10.1016/j.jhep.2017.09.007 Copyright © 2017 Terms and Conditions

Fig. 1 Immune based approaches in HCC. APC, antigen presenting cell; CTLA-4, cytotoxic T lymphocyte protein 4; HCC, hepatocellular carcinoma; MHC, major histocompatibility complex; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; TCR, T cell receptor. Journal of Hepatology 2018 68, 157-166DOI: (10.1016/j.jhep.2017.09.007) Copyright © 2017 Terms and Conditions

Fig. 2 Survival following nivolumab among patients that progressed or are intolerant to sorafenib. The survival reported in placebo-treated arms in large clinical trials addressing the second-line advanced HCC population is presented for comparison.2,22,50–52 Journal of Hepatology 2018 68, 157-166DOI: (10.1016/j.jhep.2017.09.007) Copyright © 2017 Terms and Conditions

Fig. 3 Strategies to increase the efficacy of anti-PD-1/PD-L1 blockade based on mechanism of action. CTLA-4, cytotoxic T lymphocyte protein 4; DC, dendritic cells; LAG-3, lymphocyte activation gene 3; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; TAA, tumour-associated antigen; TAM, tumour associated macrophage; TIM-3, T cell immunoglobulin and mucin-domain containing; TGFβ, transforming growth factor β; VEGF, vascular endothelial growth factor. Journal of Hepatology 2018 68, 157-166DOI: (10.1016/j.jhep.2017.09.007) Copyright © 2017 Terms and Conditions